← Leaderboards
Tony Velkov
Monash University
$5,007,693
Attributed
$11,111,750
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,111,750 · 3
By mechanism
R01$11,111,750 · 3
Top collaborators
- Gauri G Rao11 shared
- Jian Li5 shared
- Sara Elizabeth Maloney3 shared
- Keith S Kaye1 shared
Most similar at Monash University
Same institution · by research overlap
- Jian Li$20,228,860
- Roger L. Nation$2,176,961
Others in their field
Other Emerging Leaders on “Toxic Effect”
- Matthew Johnson · Duke University$56,071,536
- John Damon Chodera · Sloan-Kettering Inst Can Research$25,853,758
- Kristin Aillon · Midwest Research Institute$24,228,962
- Bronwen Shaw · Medical College Of Wisconsin$19,182,557
- Xinhua Li · Nano Terra, Inc.$17,491,533
- Thomas Denny · Duke University$16,626,143
Research focus
Toxic EffectBacteriaPharmacologySuperbugPseudomonas AeruginosaResistance DevelopmentInfectionInternationalPathogenSocietiesDisease OutbreaksHospitalsAntibiotic ResistanceAntibioticsAntibiotic TherapyAcinetobacter BaumanniiInnovationAntimicrobial ResistanceDangerousnessMedicalCostDrug KineticsHealthcarePharmacokinetics And Pharmacodynamics
Grant awards (16)
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ$1,663,595
R01 · FY2025 · AI
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ$732,598
R01 · FY2024 · AI
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ$548,207
R01 · FY2023 · AI
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach$344,692
R01 · FY2023 · AI
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach$274,311
R01 · FY2023 · AI
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ$184,555
R01 · FY2023 · AI
Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant âsuperbugsâ$676,074
R01 · FY2022 · AI
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach$625,436
R01 · FY2022 · AI
Targeting the Urgent Need for New Antibiotics against Gram-negative âSuperbugsâ$840,469
R01 · FY2021 · AI
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach$572,813
R01 · FY2021 · AI
Targeting the Urgent Need for New Antibiotics against Gram-negative âSuperbugsâ$840,469
R01 · FY2020 · AI
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach$562,520
R01 · FY2020 · AI
Targeting the Urgent Need for New Antibiotics against Gram-negative âSuperbugsâ$794,600
R01 · FY2019 · AI
Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approach$597,848
R01 · FY2019 · AI
Targeting the Urgent Need for New Antibiotics against Gram-negative âSuperbugsâ$793,759
R01 · FY2018 · AI
Targeting the Urgent Need for New Antibiotics against Gram-negative âSuperbugsâ$1,059,804
R01 · FY2017 · AI